

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449A/PTO</p> <p style="text-align: center; font-size: 1.2em; font-weight: bold;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center; font-style: italic;">(Use as many sheets as necessary)</p>		<p style="text-align: center; font-weight: bold;">Complete if Known</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;"></td> </tr> <tr> <td>Filing Date</td> <td></td> </tr> <tr> <td>First Named Inventor</td> <td>Thomas N. THOMAS</td> </tr> <tr> <td>Art Unit</td> <td></td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> <tr> <td>Attorney Docket Number</td> <td></td> </tr> </table>		Application Number		Filing Date		First Named Inventor	Thomas N. THOMAS	Art Unit		Examiner Name		Attorney Docket Number	
Application Number															
Filing Date															
First Named Inventor	Thomas N. THOMAS														
Art Unit															
Examiner Name															
Attorney Docket Number															

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p>		<div style="text-align: center; border-bottom: 1px solid black; margin-bottom: 5px;">Complete If Known</div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black;">Application Number</td> <td style="width: 50%; border-bottom: 1px solid black;"></td> </tr> <tr> <td style="border-bottom: 1px solid black;">Filing Date</td> <td style="border-bottom: 1px solid black;"></td> </tr> <tr> <td style="border-bottom: 1px solid black;">First Named Inventor</td> <td style="border-bottom: 1px solid black;">Thomas N. Thomas</td> </tr> <tr> <td style="border-bottom: 1px solid black;">Art Unit</td> <td style="border-bottom: 1px solid black;"></td> </tr> <tr> <td style="border-bottom: 1px solid black;">Examiner Name</td> <td style="border-bottom: 1px solid black;"></td> </tr> <tr> <td style="border-bottom: 1px solid black;">Attorney Docket Number</td> <td style="border-bottom: 1px solid black;"></td> </tr> </table>		Application Number		Filing Date		First Named Inventor	Thomas N. Thomas	Art Unit		Examiner Name		Attorney Docket Number	
Application Number															
Filing Date															
First Named Inventor	Thomas N. Thomas														
Art Unit															
Examiner Name															
Attorney Docket Number															
Sheet	/	of	/												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med, 346: 1468-1474, 2002.	✓
	2	Fennerty BM. NSAID-related gastrointestinal injury. Postgraduate Medicine, 110: 87-94, 2001.	✓
	3	Yeomans ND. Approaches to healing and prophylaxis of nonsteroidal antiinflammatory Drug-associated ulcers. Am. J. Medicine. 110/1A: 24S - 28S, 2001	✓
	4	GlavinGB, et al. L-deprenyl attenuates stress ulcer formation in rats. Neurosci. Letters. 70: 379-381 (1986).	✓
	5	ThyagaRajan S. Anti-tumor effect of l-deprenyl ----in rats with carcinogen-induced Mammary tumors. J. Neuroimmunol. 109: 95-104, 2000.	✓
	6	Thomas, T; et al. L-Deprenyl: nitric oxide production and dilation of cerebral blood vessels. NeuroReport, 9:1-6, 1998	✓
	7	Thomas, T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. Neurobiol. Aging. 21:343-348, 2000.	✓
	8	Thomas T, et al. Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal Antiinflammatory drugs. Exp Clin Endocrinol Diabetes. 111: 8-11, 2003.	✓
	9	Thomas, T. et al. Inhibition of LDL oxidation by the neuroprotective drug l-deprenyl. Neurol. Res. 24:169-173, 2002	✓
	10	Wallace JL and Soldato DL. The therapeutic potential of NO-NSAIDS. Fundamental & Clin Pharmacol. 17: 11-20, 2003.	✓

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.